JP7836885B2 - ホスホ－タウ抗体および使用の方法 - Google Patents

ホスホ－タウ抗体および使用の方法

Info

Publication number
JP7836885B2
JP7836885B2 JP2024515564A JP2024515564A JP7836885B2 JP 7836885 B2 JP7836885 B2 JP 7836885B2 JP 2024515564 A JP2024515564 A JP 2024515564A JP 2024515564 A JP2024515564 A JP 2024515564A JP 7836885 B2 JP7836885 B2 JP 7836885B2
Authority
JP
Japan
Prior art keywords
amino acid
tau
seq
sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024515564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534348A5 (https=
JP2024534348A (ja
Inventor
アンドレアス ジェロミン，
クリシュ ベンカト，
Original Assignee
アルツパス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルツパス， インコーポレイテッド filed Critical アルツパス， インコーポレイテッド
Publication of JP2024534348A publication Critical patent/JP2024534348A/ja
Priority to JP2025115822A priority Critical patent/JP7828500B2/ja
Publication of JP2024534348A5 publication Critical patent/JP2024534348A5/ja
Priority to JP2025239499A priority patent/JP2026034506A/ja
Application granted granted Critical
Publication of JP7836885B2 publication Critical patent/JP7836885B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96416—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2024515564A 2021-09-09 2022-09-08 ホスホ－タウ抗体および使用の方法 Active JP7836885B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025115822A JP7828500B2 (ja) 2021-09-09 2025-07-09 ホスホ－タウ抗体および使用の方法
JP2025239499A JP2026034506A (ja) 2021-09-09 2025-12-08 ホスホ－タウ抗体および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163242437P 2021-09-09 2021-09-09
US63/242,437 2021-09-09
PCT/US2022/042963 WO2023039107A2 (en) 2021-09-09 2022-09-08 Phospho-tau antibodies and methods of use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025115822A Division JP7828500B2 (ja) 2021-09-09 2025-07-09 ホスホ－タウ抗体および使用の方法
JP2025239499A Division JP2026034506A (ja) 2021-09-09 2025-12-08 ホスホ－タウ抗体および使用の方法

Publications (3)

Publication Number Publication Date
JP2024534348A JP2024534348A (ja) 2024-09-20
JP2024534348A5 JP2024534348A5 (https=) 2025-07-17
JP7836885B2 true JP7836885B2 (ja) 2026-03-27

Family

ID=85507770

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2024515564A Active JP7836885B2 (ja) 2021-09-09 2022-09-08 ホスホ－タウ抗体および使用の方法
JP2025115822A Active JP7828500B2 (ja) 2021-09-09 2025-07-09 ホスホ－タウ抗体および使用の方法
JP2025239499A Pending JP2026034506A (ja) 2021-09-09 2025-12-08 ホスホ－タウ抗体および使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025115822A Active JP7828500B2 (ja) 2021-09-09 2025-07-09 ホスホ－タウ抗体および使用の方法
JP2025239499A Pending JP2026034506A (ja) 2021-09-09 2025-12-08 ホスホ－タウ抗体および使用の方法

Country Status (7)

Country Link
US (3) US12276671B2 (https=)
EP (1) EP4399524A4 (https=)
JP (3) JP7836885B2 (https=)
KR (1) KR102888596B1 (https=)
CN (1) CN118235043A (https=)
CA (1) CA3231228A1 (https=)
WO (1) WO2023039107A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023039107A2 (en) 2021-09-09 2023-03-16 Alzpath, Inc. Phospho-tau antibodies and methods of use
KR20250173598A (ko) * 2023-03-16 2025-12-10 알즈패스, 인크. 신경퇴행성 질환의 진단 및 치료 방법
CN119470917A (zh) * 2024-11-14 2025-02-18 苏州智研医康医疗科技有限公司 一种检测人血中阿尔茨海默病相关蛋白的试剂盒及检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112505322A (zh) 2020-10-16 2021-03-16 威海纽普生物技术有限公司 阿尔茨海默病标志物p-Tau217检测试剂盒及其制造方法
WO2024192404A1 (en) 2023-03-16 2024-09-19 Alzpath, Inc. Methods of diagnosing and treating neurodegenerative disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US20040219509A1 (en) 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7604956B2 (en) 2004-03-01 2009-10-20 Biotraces, Inc. Supersensitive immunoassays
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
US7914734B2 (en) 2007-12-19 2011-03-29 Singulex, Inc. Scanning analyzer for single molecule detection and methods of use
US20110177509A1 (en) 2008-07-23 2011-07-21 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
JP2013518927A (ja) * 2010-02-09 2013-05-23 ブリストル−マイヤーズ スクイブ カンパニー 免疫アッセイ標準物質およびアッセイ内の校正標準物質を用いる臨床バイオマーカーの測定
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
WO2012142300A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
MX350311B (es) 2011-12-20 2017-09-01 Janssen Biotech Inc Anticuerpos anti-phf-tau y sus usos.
NZ630542A (en) * 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
NZ775762A (en) * 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
GB201518675D0 (en) * 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
US20180080945A1 (en) * 2016-09-20 2018-03-22 Nanosomix, Inc. Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
KR102048987B1 (ko) * 2017-02-22 2019-11-27 한국과학기술연구원 신경퇴행성 장애의 진단을 위한 정보 제공 방법
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
WO2019085804A1 (en) 2017-11-02 2019-05-09 Peking University Methods and use for detecting and inhibiting cell-free mg53
EP3706795A4 (en) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
US20200377609A1 (en) 2018-02-14 2020-12-03 Kite Pharma, Inc. Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
WO2020105700A1 (ja) 2018-11-22 2020-05-28 富士レビオ株式会社 抗体コンジュゲート
KR102905634B1 (ko) 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
WO2021178545A1 (en) 2020-03-03 2021-09-10 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Proteomic screening for diseases
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2023039107A2 (en) 2021-09-09 2023-03-16 Alzpath, Inc. Phospho-tau antibodies and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112505322A (zh) 2020-10-16 2021-03-16 威海纽普生物技术有限公司 阿尔茨海默病标志物p-Tau217检测试剂盒及其制造方法
WO2024192404A1 (en) 2023-03-16 2024-09-19 Alzpath, Inc. Methods of diagnosing and treating neurodegenerative disorders

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Development and characterization of a novel monoclonal antibody to Tau p217 in Alzheimer's disease murine models and human disease tissue"，2023年01月01日，https://media.cellsignal.com/www/pdfs/science/posters/2023/Development_and_characterization_of_a_novel_monoclonal_antibody_to_Tau_p217_in_Alzheimers_diseas_murine_models_and_human_disease_tissue.pdf
Adam M. BRICKMAN et al.，"Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study"，Alzheimer's & Dementia，2021年02月13日，Vol. 17, No. 8，p.1353-1364，DOI: 10.1002/alz.12301
Cristina D’ABRAMO et al.，"Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use"，Journal of Personalized Medicine，2020年09月08日，Vol. 10, No. 3，p.116，DOI: 10.3390/jpm10030116
Denghong ZHANG et al.，"P-tau217 correlates with neurodegeneration in Alzheimer’s disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy"，Neuron，2024年05月，Vol. 112, No. 10，p.1676-1693.e12，DOI: 10.1016/j.neuron.2024.02.017
Ebru ERCAN-HERBST et al.，"A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer’s disease brain"，Acta Neuropathologica Communications，2019年12月，Vol. 7, No. 1，DOI: 10.1186/s40478-019-0823-2
Gallen TRIANA-BALTZER et al.，"Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid"，Journal of Alzheimer's Disease，2020年10月13日，Vol. 77, No. 4，p.1417-1430，DOI: 10.3233/JAD-200463
Jing LU et al.，"Blood tau‐PT217 contributes to the anesthesia/surgery‐induced delirium‐like behavior in aged mice"，Alzheimer's & Dementia，2023年05月30日，Vol. 19, No. 9，p.4110-4126，DOI: 10.1002/alz.13118
Joelle ROSSEELS et al.，"Tau Monoclonal Antibody Generation Based on Humanized Yeast Models"，Journal of Biological Chemistry，2015年02月，Vol. 290, No. 7，p.4059-4074，DOI: 10.1074/jbc.M114.627919
Marc SUAREZ‐CALVET et al.，"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected"，EMBO Molecular Medicine，2020年11月10日，Vol. 12, No. 12，DOI: 10.15252/emmm.202012921
Sebastian PALMQVIST et al.，"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease"，EMBO Molecular Medicine，2019年11月11日，Vol. 11, No. 12，DOI: 10.15252/emmm.201911170
Sherif BAYOUMY et al.，"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231"，Alzheimer's Research & Therapy，2021年12月04日，Vol. 13, No. 1，DOI: 10.1186/s13195-021-00939-9

Also Published As

Publication number Publication date
US12276671B2 (en) 2025-04-15
EP4399524A4 (en) 2025-10-08
CN118235043A (zh) 2024-06-21
EP4399524A2 (en) 2024-07-17
US12339290B2 (en) 2025-06-24
CA3231228A1 (en) 2023-03-16
US20250277799A1 (en) 2025-09-04
JP2026034506A (ja) 2026-02-27
KR102888596B1 (ko) 2025-11-20
KR20240067082A (ko) 2024-05-16
US20240353428A1 (en) 2024-10-24
JP7828500B2 (ja) 2026-03-11
US20240360206A1 (en) 2024-10-31
JP2024534348A (ja) 2024-09-20
WO2023039107A2 (en) 2023-03-16
JP2025137567A (ja) 2025-09-19
KR20250108128A (ko) 2025-07-15
WO2023039107A3 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
JP7828500B2 (ja) ホスホ－タウ抗体および使用の方法
AU2017339809B2 (en) Improved methods of assessing UCH-L1 status in patient samples
CN116348769A (zh) 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定
TW201938584A (zh) 抗pla2-gib抗體及其用途
US12596119B2 (en) Analyte detection immunoassay
JP7308914B2 (ja) ウイルス抗原の血清学的検出方法
JP7830486B2 (ja) オキシントモジュリン結合分子、及びそれらの使用
JP7044721B2 (ja) Ｈｃｖコア抗原の迅速な検出のための前処理法
JP2026509486A (ja) 神経変性障害を診断および処置する方法
KR102959196B1 (ko) 포스포-타우 항체 및 사용 방법
HK40112938A (zh) 磷酸化-tau抗体和使用方法
BR122025017050A2 (pt) Anticorpo anti-tau ou fragmento de ligação ao antígeno do mesmo
EP3775900A1 (en) High throughput method for measuring the protease activity of complement c3 convertase
CN116789817A (zh) Tau重组抗原、靶向Tau蛋白重组抗体与检测Tau蛋白的试剂盒
EA049359B1 (ru) Анализ проб, полученных из крови, для обнаружения таупатии или амилоидогенного заболевания

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250709

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260316

R150 Certificate of patent or registration of utility model

Ref document number: 7836885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150